Treatment of the tumour appeared to have more effect were examined for paraneoplastic antibodies, 79 had the presumptive diagnosis of limbic encephalitis, dementia, on the neurological outcome than the use of immune modulation. Improvement was observed in 38% of anticognitive dysfunction, or confusion. Fifty of these patients fulfilled our criteria for PLE. Pathological confirmation Hu patients, 30% of anti-Ta patients and 64% of patients without these antibodies. was obtained in 12 patients. The commonly associated
Introduction
Based upon prior case reports and their own series, Corsellis report the spectrum of neurological symptoms and tumours in 50 patients with PLE and analyse the utility of the detection and colleagues first described paraneoplastic limbic encephalitis (PLE) as a clinicopathological entity 30 years of paraneoplastic antibodies and other diagnostic tests for this disorder. ago (Corsellis et al., 1968) . To date, 137 patients with PLE have been reported in the English literature, 32 of them supported by autopsy (reviewed in Table 1 ). Most reports have emphasized the clinical and pathological involvement
Design and methods
The clinical and laboratory data of 79 patients with of the limbic structures, but the majority of patients had variable involvement of other areas of the nervous system, presumptive paraneoplastic disorders, including limbic encephalitis, memory problems, dementia, cognitive dysmainly the brainstem (Henson et al., 1954; Bakheit et al., 1990) . The diagnosis of PLE is often difficult because function or confusion, were reviewed. These patients were identified from a database of 1047 patients with suspected similar symptoms (seizures, memory problems, irritability, depression, confusion and dementia) can be caused by many paraneoplastic neurological syndromes, whose sera or CSF were examined for antineuronal antibodies at Memorial other cancer-related complications, including brain metastases, toxic and metabolic encephalopathies, infections Sloan-Kettering Cancer Center. Twelve patients were examined by the authors (J.B.P., J.D.). Information on the (especially with herpes simplex encephalitis) and the sideeffects of cancer therapy (Posner, 1995) . In addition, other patients was obtained from their primary physicians. The diagnosis of PLE required neuropathological examination neurological symptoms frequently precede the detection of the tumour, further confounding the diagnosis of the neurological (biopsy or autopsy), or all four of the following criteria: (i) a clinical picture of short-term memory loss, seizures, or disorder as paraneoplastic in origin.
Antineuronal antibodies, when present in the serum and psychiatric symptoms suggesting involvement of the limbic system; (ii) an interval of Ͻ4 years between the onset CSF, facilitate the diagnosis of PLE and often allow the early detection of the associated tumour (Alamowitch et al., 1997) .
of neurological symptoms and the cancer diagnosis; (iii) exclusion of other cancer-related complications (metastasis, However, the frequency of antineuronal antibodies in patients with PLE is largely unknown (Dalmau et al., 1999a) . We infection, metabolic and nutritional deficits, cerebrovascular on T 2 -weighted images or atrophy on T 1 -weighted images; and EEG showing slow-or sharp-wave activity in one or both temporal lobes.
Patients with PLE
Serum (and CSF when available) was examined for Twenty-three women and 27 men, ranging in age from 11 to antineuronal antibodies using immunoblots of human 75 years (median 55 years), were included in the study. neuronal protein extracts, recombinant paraneoplastic proteins Neurological dysfunction developed before the tumour (HuD, CDR62, Nova-1, Ma1 and Ma2) and immunodiagnosis in 29 patients (median 3.5 months, range 0.5-33 histochemistry on sections of human and rat cerebral cortex, months) and after the tumour diagnosis in 19 (median 5 as reported previously (Dalmau and Rosenfeld, 1995; months, range 1-48 months). Two patients had no tumour 1999). The presence of anti-CV2 antibodies was examined identified during the course of the disease; one had anti-Hu using immunohistochemistry with rat brain tissue fixed in antibodies and the other anti-Ma antibodies (see Discussion). paraformaldehyde (Honnorat et al., 1996) .
The associated tumours are shown in Table 2 . Cancer of the lung (50%), particularly small-cell lung cancer (SCLC) (40%), and testicular germ-cell tumours (20%) were the most frequently found neoplasms. Thirty-eight patients had
Results
localized disease and 5 had distant metastasis; no staging Among 79 patients with the presumptive diagnoses of limbic information was available for five patients. encephalitis, memory problems, dementia, cognitive dysNeurological symptoms developed over days or weeks in function or confusion, 50 fulfilled our criteria for PLE.
41 (82%) patients. Slower development of symptoms, over Twelve of these 50 patients have been reported previously months, occurred in 8 patients; for 1 patient the evolution of (Ahern et al., 1994; Cunningham and Burt, 1994; Cher et al., symptoms was not known. 1995; Alamowitch et al., 1997; Aydiner et al., 1998; Burton Presenting symptoms included memory loss and confusion (24 patients), seizures (6 patients; 3 psychomotor, 1 focal et al., 1997; Bennett et al., 1999; Voltz et al., 1999) . *'Abnormal' indicates unilateral (10) or bilateral (15) temporal lobe abnormalities on T 2 -weighted sequences; in 5 of these 25 patients the lesions showed contrast enhancement. Three patients without temporal-limbic MRI findings had white matter abnormalities in other regions: 1 multifocal, 1 diffuse, and 1 perithalamic and deep white matter changes. † 'Abnormal' indicates inflammatory changes, including increased proteins (24/47), pleocytosis (24/47), increased IgG synthesis (15/15) and oligoclonal bands (10/13). ‡ 'Abnormal' indicates temporal epileptic focus (unilateral 10; bilateral 3), periodic lateralized epileptiform discharges (2), general non-specific slowing (9) and abnormal but not specified (3). § Abnormal findings include temporal abnormalities (5) detailed in the text, multifocal white matter lesions (1), cerebral or cerebellar atrophy (3) and frontal lobe metastasis (1). ¶ Detailed in the text. # These include diffuse, non-specific slowing (3) and posterior triphasic waves (1).
facial twitching, 1 focal motor with secondary generalization, loss (22 patients), seizures (25 patients) or both (20 patients).
Among the 25 patients with seizures, 10 had temporal lobe 1 generalized tonic-clonic), hypothalamic dysfunction (6 patients; 3 hypersomnia, 2 hyperthermia, 1 panhypoor psychomotor seizures, 6 generalized seizures, and 9 a combination of seizure types. Only 3 patients did not have pituitarism), psychiatric abnormalities (6 patients; 5 depression, 1 hallucinations), and symptoms of involvement seizures or short-term memory loss: two developed a confusional state without epileptic activity on EEG and the of other areas of the nervous system (7 patients; 3 sensory neuronopathy, 2 cerebellar ataxia, 1 dizziness, 1 diplopia).
other developed hypothalamic dysfunction characterized by diabetes insipidus, loss of libido and hypothyroidism. In For 1 patient, information about presenting symptoms was not available.
these three patients the MRI showed mesial temporal changes compatible with PLE. Table 3 shows the main symptoms during the course of the disease and the total number of patients having each Forty-nine patients had neuroimaging studies (44 MRI and 5 CT) ( Table 4 ). The most frequent MRI abnormalities were symptom. Overall, 47 patients developed short-term memory identified on T 2 -weighted images and involved the mesial selective diffuse reactivity with the neuropil, but was negative in immunoblot studies; and the serum of a patient with nonaspect of one (10 patients) or both (15 patients) temporal lobes (Fig. 1) . In 5 patients, the mesial-temporal MRI SCLC showed faint labelling of the neuronal cytoplasm with negative immunoblot findings. Sixteen patients had no abnormalities enhanced after contrast administration. A biopsy from the enhancing area obtained in 4 patients showed antineuronal antibodies. None of the sera contained anti-CV2 antibodies. inflammatory infiltrates and neuronal loss (Fig. 2) . In addition to the temporal lobe findings, 8 patients had MRI Overall, 39 (78%) patients had temporal lobe abnormalities on MRI studies and/or positive paraneoplastic antibodies in abnormalities in other areas: 4 in the brainstem, 4 in the hypothalamus, 1 in the thalamus, 1 in the cingulate gyrus their serum. When the abnormal findings in one or both of these tests were combined with the detection of abnormal and 1 in the basal frontal lobe; none of these abnormalities, except 1 in the hypothalamus, enhanced with contrast CSF, the number of patients with at least two abnormal tests was 49. The remaining patient, with Hodgkin's disease, had material. Three patients without temporal-limbic MRI findings had abnormalities involving other areas of the brain biopsy findings supporting the diagnosis of PLE. On the basis of the presence or absence of anti-Hu nervous system (Table 4) .
The CSF was examined in 49 patients, and 40 showed one and anti-Ta antibodies, we established three immunological groups of PLE patients. For practical purposes the two or more of the following abnormalities: 24 of 47 had pleocytosis (Ͼ5 cells/mm 3 ; range 9-100 cells/mm 3 , median patients with anti-Ma antibodies and the 4 patients with noncharacterized antineuronal antibodies were included in the 29); 24 of 27 had elevated proteins (Ͼ45 mg/dl; range 47-170, median 74); 10 of 13 had oligoclonal bands; and 15 of group of patients without antibodies (Table 5 ). In 6 patients (3 anti-Hu, 3 anti-Ta) the detection of these antibodies led 15 had intrathecal synthesis of IgG. Only 7 patients had increased proteins as an isolated finding. None of 49 patients to the diagnosis of the paraneoplastic syndrome and assisted in identifying the underlying tumour. had malignant cells in the CSF (Table 4) .
Paraneoplastic antibodies were identified in the serum, Of 18 patients with anti-Hu antibodies, 16 had SCLC, 1 was reported to have adenocarcinoma of the lung (the CSF, or both, of 30 patients (60%): in 18 patients they were anti-Hu antibodies, in 10 they were anti-Ta antibodies (also tumour was not examined by us), and no tumour was identified in another patient. All patients with anti-Ta antibodies had known as anti-Ma2 antibodies) and in 2 they were anti-Ma antibodies (Figs 3 and 4) . Four patients had antineuronal testicular germ-cell tumours. In the group of patients without antibodies or with atypical antibodies, 8 (36%) had cancer antibodies that have not been characterized: the serum from a patient with breast cancer reacted with several proteins in the of the lung (4 SCLC), 4 adenocarcinoma of the breast, 2 immature teratoma, 2 Hodgkin's disease, 1 plasma cell 30-40 kDa range expressed predominantly in the cytoplasm of hippocampal pyramidal cells; the serum from a patient with dyscrasia, 1 malignant thymoma, 1 adenocarcinoma of the colon, 1 chronic myeloid leukaemia and 1 ovarian cancer non-SCLC reacted with several proteins in the range of 40-60 kDa expressed in the cytoplasm of neurons and Purkinje (Table 5) . Seventy-eight per cent of patients with PLE and anti-Hu cells; the serum from a patient with ovarian cancer showed antibodies had symptoms suggesting dysfunction of areas of instances, the main findings were perivascular cuffing and interstitial infiltrates of lymphocytes, microglial proliferation, the nervous system distant from the limbic system (brainstem, cerebellum, dorsal root ganglia, cerebral cortex, spinal cord gliosis and neuronal degeneration (Fig. 2) . Three autopsy studies had results of detailed neuropathological examination and autonomic nervous system) ( Table 5 ). These areas were less likely to be involved in patients without antibodies or showing chronic encephalitis without viral inclusion bodies that was not restricted to the limbic regions. with atypical antibodies (41%).
Compared with the anti-Hu patients (median age 61.5 Clinical follow-up was available for 34 patients (median 8 months, range 1-84 months) ( Table 6 ). Treatment of the years), the anti-Ta patients were younger (median age 34 years) and had more restricted involvement of the limbic tumour appeared to be associated with improvement of the neurological syndrome in 11 of the 15 patients (73%) in whom system and brainstem (80%); only 2 patients had other symptoms (1 with involvement of the basal ganglia and 1 this assessment was possible. Eighteen patients received one or more immune modulatory treatments for the paraneoplastic with cerebellar dysfunction). As part of the limbic symptoms, 70% of these patients had severe hypothalamic dysfunction disorder: 12 corticosteroids (60-100 mg prednisone), 4 cyclophosphamide, 4 intravenous immunoglobulin, 5 plasma (clinical details of these patients have been reported elsewhere (Voltz et al., 1999) . Unlike patients with anti-Hu antibodies, exchange, and 1 removal of plasma IgG by immunoadsorption with a protein-A column. Four of these 18 patients (22%) the anti-Ta patients did not develop signs of dorsal root ganglion involvement or myelitis.
had partial neurological improvement closely related to the dates when they were treated with immune modulation, Pathological examination of the brain was obtained in 12 patients: 8 had a brain biopsy and 4 an autopsy. In all although all 4 had simultaneous treatment of the tumour. recovery). Improvement was observed in 5 of 13 (38%) patients with anti-Hu antibodies, 3 of 10 (30%) with anti-Ta antibodies and 7 of 11 (64%) without detectable antibodies (Tables 5 and 6 ).
Patients without PLE
The sera of 29 patients affected with memory loss, cognitive dysfunction, or seizures, but who did not fulfil our strict criteria for PLE, were examined for antineuronal antibodies. There were 16 men and 13 women with a median age of 64.5 years (range 29-92 years). Thirteen patients had cancer: neurological symptoms developed before the tumour years, range 1-19 years). Tumours included SCLC in 2 patients, non-SCLC tumours in 2 patients, renal cell cancer in 2 patients, breast cancer in 1 patient, adenocarcinoma of Irrespective of the treatment used, neurological symptoms progressed in 11 patients (resulting in death in 6), remained the parotid gland in 1 patient, testicular germ-cell tumour in 1 patient, lymphoma in 1 patient, multiple myeloma in 1 stable in 8 and improved in 15 (14 partial recovery, 1 full patients and lung nodules (without biopsy) in 2 patients. No colleagues described a patient with 'undifferentiated bronchial carcinoma and an encephalitic-like picture in the limbic systemic tumour was identified in the other 16 patients after a median follow-up of 12 months (range 1 month to 8 years).
system' (Störring et al., 1962) . In 1965, Yahr and colleagues reported a patient with 'encephalopathy associated with CSF was examined in 15 patients: 4 showed inflammatory abnormalities, 6 showed increased proteins only and 5 were carcinoma' who had SCLC and limbic system inflammatory changes (Yahr et al., 1965) . In 1967, Ulrich and colleagues normal (Table 4) . Three patients harboured atypical antibodies that reacted with neurons; none of these antibodies was reported a patient with SCLC and neuronal degeneration in Ammon's horn and elsewhere with some perivascular similar to any of the 4 atypical antibodies found in the PLE patients. The other 26 patients were negative for antibodies. lymphocytic cuffing (Ulrich et al., 1967) . The name limbic encephalitis was coined by Corsellis and MRI was obtained in 22 patients. Temporal lobe abnormalities were identified in 5 patients, whose final colleagues (Corsellis et al., 1968) when they reported three additional patients and extensively reviewed the prior diagnoses were: herpes simplex encephalitis in 2 patients (1 associated with glioma); metastasis of renal cell cancer literature, including those patients first reported by Brierley and colleagues (Brierley et al., 1960) . This description of in 1 patient; bilateral temporal lobe abnormalities with frontoparietal and periventricular white matter changes in limbic encephalitis generated more reports, and by 1990 Bakheit and colleagues were able to report three new patients 1 patient with non-caseating bone marrow granulomatosis of uncertain significance; and bilateral temporal lobe T 2 -with PLE, and reviewed the extant literature, which consisted of 16 cases that had been verified clinically and pathologically weighted abnormalities with contrast enhancement in 1 patient with primary CNS lymphoma, who eventually developed (Bakheit et al., 1990) . Once the relationship between cancer and the nervous system lesion had been established, three involvement of the left basal ganglia and occipital lobe.
The final diagnoses of the patients without MRI pathogenic hypothesis were advanced: (i) a (not further defined) degeneration of the nervous system in which the abnormalities in the temporal lobes included 1 of each of the following: viral encephalitis; primary CNS lymphoma; inflammatory infiltrates were a secondary 'reaction to the tissue breakdown' (Verhaart, 1961; Ulrich et al., 1967) ; (ii) Creutzfeldt-Jakob disease; ischaemic cerebrovascular disease; psychiatric disorder with pseudodementia; frontal a viral infection (Corsellis et al., 1968) ; and (iii) an immunemediated response against the nervous system (Russell, 1961) . lobe metastasis; and intracranial hypertension due to remote subarachnoidal haemorrhage; and 17 patients had primary
The third hypothesis is the currently accepted one.
Despite the now fairly large number of patients reported, degenerative dementia (either of the Alzheimer type or of unknown cause).
the diagnosis of PLE remains difficult. The presenting symptoms may be different from those considered typical of the disorder (i.e. short-term memory loss, seizures, and mood or behavioural changes). In 27% of our patients these
Discussion
In 1960, Brierley and colleagues described three patients symptoms were not part of the presentation of the paraneoplastic disorder. Usually, patients are not known to suffering from 'subacute encephalitis of later adult life mainly affecting the limbic areas' (Brierley et al., 1960) . At autopsy, have cancer, as occurred in 60% of our patients. Symptoms resembling PLE are frequent in cancer patients and may the first patient had a small leiomyoma of the left kidney but no other evidence of malignancy. The second patient had result from multiple different metastatic and non-metastatic complications (Clouston et al., 1992; Hosaka and Aoki, 1996 ; several mediastinal and hilar lymph nodes 'extensively replaced by oat-shaped cells, appearing identical to those Spiegel, 1996; Porta-Etessam, 1999) . In fact, a 1956 report of a 'mental disorder associated with primary lung carcinoma' seen in anaplastic bronchial carcinoma'; no tumour was found in the lungs or elsewhere in the body. The third patient described three patients who probably suffered from hepatic encephalopathy (Charatan and Brierley, 1956) . With the had 'an encapsulated mass at the root of the right lung' which consisted of fibrotic lymph nodes. Although one of exception of the anti-Hu antibody in some patients with SCLC and the anti-Ta antibody in patients with testicular the authors had previously reported patients with a 'mental disorder associated with primary lung carcinoma' (Charatan tumours, there are no known serological markers of PLE. In the current study, 60% of the patients had paraneoplastic and Brierley, 1956) , they believed that it was 'most unlikely that this finding [lung cancer in patient 2] is in any way antibodies in their serum (see below). Identification of these antibodies, when combined with characteristic MRI findings, related to the encephalitis but its occurrence should be noted'. They also noticed that a lung cancer had been clinically helped establish the diagnosis of PLE in 78% of the patients. Symptoms of involvement of areas of the nervous system suspected in patient 3 but they failed to consider that the fibrotic lymph nodes may have represented a remitting distant from the limbic system (particularly the brainstem and cerebellum) are frequent in patients with PLE. This tumour. In 1961, Verhaart described two patients with inflammatory lesions of the medial temporal lobe and nerve occurred in 60% of our patients and similar findings were recognized by Bakheit and colleagues, who found that only cell loss in the brainstem and cerebellum, both of whom had tumour in the mediastinal lymph nodes but no identifiable 6 of 19 (32%) patients had isolated limbic encephalitis (Bakheit et al., 1990 ). pulmonary lesion (Verhaart, 1961) . In 1962, Störring and Typical MRI findings of PLE include unilateral or bilateral be confirmed by PCR (polymerase chain reaction) analysis of the CSF or brain biopsy (Cinque et al., 1996) . mesial temporal lobe abnormalities that are best seen on T 2 -Symptoms and pathological findings of limbic encephalitis weighted images. On T 1 sequences, the temporal-limbic have been reported in the absence of cancer (Brierley et al., regions may be hypointense and atrophic, and may sometimes 1960; Langston et al., 1975; Horoupian and Kim, 1982 ; enhance with contrast injection. These abnormalities, Daniel et al., 1985; Kohler et al., 1988; Kepes et al., 1990) . although well known (Dirr et al., 1990; Lacomis et al., 1990) ,
We believe that in most cases a cancer was present but not had not been examined in a large series of patients. In our detected. In one of our patients with PLE and life-threatening study, 64% of the patients with PLE had abnormal MRI neurological deterioration, the family consented to right studies, which in 89% of the cases showed the changes orchiectomy because of the detection of serum anti-Ta indicated above. Patients with herpes simplex encephalitis antibodies and ultrasound findings of a mild abnormality in may have similar MRI findings in the early stages of the the right epididymis (consistent with epididymitis). The disease. However, these patients usually develop prominent original pathological evaluation was negative for testicular signs of oedema and mass effect involving one or both cancer, but detailed review of the slides demonstrated inferior-medial temporal lobes, the inferior frontal lobes and microscopic intratubular germ-cell tumour (Dalmau et al., the cingulate gyrus. In addition, gyral enhancement is present 1999b). in more than half of the patients and signs of haemorrhage
We compared the histological types of tumours of our are not uncommon (Demaerel et al., 1992; Kapur et al., 1994) .
patients with those reported in the English literature, bearing CSF analysis assists in making the diagnosis of PLE in in mind two considerations. First, 53 of 137 reported patients two ways. First, a negative cytological analysis for malignant come from three studies of patients selected on the basis cells in combination with the absence of meningeal of suffering from SCLC or harbouring anti-Hu antibodies enhancement on the MRI helps exclude leptomeningeal (Dalmau et al., 1992; Alamowitch et al., 1997; Lucchinetti metastases. Secondly, the detection of inflammatory et al., 1998) . Secondly, 12 of our patients have been reported abnormalities (pleocytosis, intrathecal synthesis of IgG, previously. Thus, after excluding these 65 patients from Table oligoclonal bands) supports the diagnosis of an inflammatory 1, the remaining 72 patients were compared with the 50 or immune-mediated neurological disorder; 64% of our patients of the current study (Table 2 ). This comparison patients had one or more of these abnormalities. We did not revealed a preferential association of PLE with certain find any patient with antibodies present only in the CSF; tumours: SCLC, germ-cell tumours of the testis, breast cancer, however, two patients had barely detectable serum anti-Ta Hodgkin's lymphoma, immature teratoma and thymoma. titres, while the CSF titres were several orders of magnitude
The reason for the preferential association of PLE with higher (data not shown).
certain tumours is unknown. SCLC and testicular germ-cell The EEG has limited usefulness in making the diagnosis tumours express a number of proteins (including the Hu and of PLE, but it is useful in assessing whether changes in the Ma proteins) that in normal adult tissues are restricted to level of consciousness or behaviour are related to temporal neurons and germ cells of the testis (Carpentier et al., 1998 ; lobe seizures. In a review of 19 patients, Bakheit and Dalmau et al., 1999c; Voltz et al., 1999) . In addition, these colleagues identified temporal lobe seizures in only one tissues are immunoprivileged by the presence of endothelial patient (Bakheit et al., 1990) . In our study, the incidence of barriers and atypical or absent expression of antigen-EEG abnormalities was limited by the fact that only patients presenting molecules (MHC class I) (Haas et al., 1988 ; in whom seizures were suspected received EEG evaluation. Neumann et al., 1997; Corriveau et al., 1998) . These findings Nevertheless, among the 35 patients with EEG studies, 45% suggest a mechanism whereby the tumour expression of had epileptic activity.
brain/testis proteins is the trigger of autoimmunity against Symptoms resembling PLE may result from several the nervous system. This hypothesis is supported by our disorders, including systemic lupus erythematosus (Glanz study, in which SCLC and testicular germ-cell tumours et al., 1998; Stubgen et al., 1998) , Wernicke-Korsakoff were consistently associated with antineuronal antibodies in encephalopathy with or without cancer (De Reuck et al., patients with PLE. Immunological disturbances have also 1981; Engel et al., 1991) , toxic effects of doxifluridine (an been identified in patients with PLE and thymoma (Antoine antineoplastic agent) (Heier and Fossa, 1986) and herpes et al., 1995) , a tumour frequently related to other autoimmune simplex encephalitis (Aimard et al., 1979; Perentes and neurological disorders, including myasthenia gravis and Herbort, 1984) . Two of our patients with PLE were initially neuromyotonia (Newsom-Davis and Mills, 1993; considered to have herpes simplex encephalitis and received Drachman, 1994) . treatment with acyclovir without neurological improvement.
Thirty of our patients (60%) had positive paraneoplastic However, patients with herpes simplex encephalitis usually antibodies (anti-Hu, anti-Ta or anti-Ma). We took into develop acute or subacute mental confusion and seizures that consideration a possible bias of serum referral to our often lead to stupor or coma. The MRI findings (see above) laboratory for anti-Ta antibody testing. However, only 2 of and the presence of red blood cells in the CSF point to the the 10 patients with positive anti-Ta antibodies were included in the study after the discovery of these antibodies (Voltz diagnosis of herpes simplex encephalitis, which diagnosis can et al., 1998); the other 8 were retrospectively identified from antibodies, and only 2 had MRI abnormalities similar to those identified in PLE; one had herpes simplex encephalitis, the 1047 patients in the database.
On the basis of the presence of paraneoplastic antibodies, and the other a primary CNS lymphoma that eventually showed multifocal areas of enhancement. we established three immunological subsets of PLE (Table  5 ) that differ from each other by the age of the patients, the From this and previous studies (Table 1 ), it appears likely that PLE is an immune-mediated disorder that can be caused type of tumour association and some clinical features. The most distinctive of these include the presence of symptoms by several types of tumour-induced autoimmunity. When PLE is suspected, the following tests should be considered: (i) from areas outside the limbic system in most anti-Hu patients and the frequent hypothalamic and brainstem involvement in MRI of the brain without and with contrast; (ii) paraneoplastic antibody testing of serum and CSF; (iii) CSF studies to rule anti-Ta patients. In addition, PLE patients with anti-Ta antibodies are more likely to have abnormal MRI findings out the presence of metastatic cells and demonstrate the presence of inflammatory abnormalities (oligoclonal bands, than other PLE patients.
It is important to note that the group of patients 'with intrathecal synthesis of IgG, pleocytosis); and (iv) EEG studies, particularly in patients with an acute confusional state no antibodies or with other antibodies' is an ill-defined, heterogeneous group that includes patients without of unknown cause. Patients older than 40 years, particularly if they are smokers, should be examined for serum and CSF antineuronal antibodies, and 6 patients with antibodies other than anti-Hu and anti-Ta (4 non-characterized and 2 antianti-Hu antibodies; the detection of this antibody confirms that the limbic syndrome is paraneoplastic and indicates that Ma). One anti-Ma patient was a woman, without a cancer diagnosis, who developed confusion, lethargy and T 2 MRI the tumour is probably SCLC. In patients older than 40 years without paraneoplastic antibodies, the tumours most abnormalities involving the medial temporal lobes, hypothalamus and upper midbrain; the other was a woman frequently encountered are non-SCLC, carcinoma of the breast and thymoma; however, the absence of anti-Hu with breast cancer, typical symptoms of PLE, and T 2 MRI abnormalities in the medial temporal lobes. Unlike other antibodies does not rule out the possibility that the underlying tumour is SCLC. Patients younger than 40 years, particularly anti-Ma sera that react similarly with both Ma1 and Ma2 proteins (Dalmau et al., 1999c) , the sera and CSF of these if they are male, should be studied for serum and CSF antiTa antibodies; the detection of these antibodies indicates that two patients showed more reactivity with Ma2 than Ma1 (data not shown). This finding and the data from patients the disorder is paraneoplastic and that the tumour is likely to be located in testis. In patients younger than 40 years with anti-Ta antibodies (which recognize Ma2) (Voltz et al., 1999) suggest that Ma2 contains epitopes related to and without paraneoplastic antibodies, the tumours most frequently involved are Hodgkin's lymphoma and immature autoimmunity associated with limbic dysfunction.
In contrast to most paraneoplastic syndromes of the CNS, teratoma. Regardless of the antineuronal antibody status, MRI studies show T 2 abnormalities in mesial temporal which do not improve with treatment, PLE may respond to therapy. In our study, 44% of patients with a median followregions in 57% of the patients; these findings, although not pathognomonic, are highly suggestive of PLE, particularly if up of 8 months showed neurological improvement regardless of the type of treatment. Treatment of the tumour appeared they are associated with inflammatory changes in the CSF. Although we did not find anti-CV2 antibodies, which are not to have more effect on neurological improvement than the use of immunosuppressive therapies. We found similar results consistently associated with PLE, there are 3 reported patients (2 with SCLC and 1 with thymoma) in whom detection of in the literature review of 137 patients (Table 1) . Information about the response to treatment was available for 107 anti-CV2 antibodies helped to establish the paraneoplastic origin of a limbic dysfunction (Antoine et al., 1995; Honnorat patients; 25 (23%) had neurological improvement, in 24 the improvement was attributed to tumour treatment, and in 1 it et al., 1996) . From our study and review of the literature, no definitive was attributed to symptomatic treatment (haloperidol). These findings, coupled with the high frequency of limited stage treatment is available for PLE. However, early identification and treatment of the tumour is the approach that appears to disease (88% of our patients, irrespective of antineuronal antibody status), underscore the need for prompt detection and offer the greatest chance for neurological improvement. treatment of the tumour, which may improve the neurological deficits and control the cancer.
We are aware that some of our findings may result from
